Abstract
Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma. Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m2 over 30 min on days 1 and 8 every 21 days. Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35% of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4%), nine had stable disease (39%), and twelve had increasing disease (52%). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22% of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity. Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.
Original language | English (US) |
---|---|
Pages (from-to) | 118-121 |
Number of pages | 4 |
Journal | Gynecologic oncology |
Volume | 121 |
Issue number | 1 |
DOIs | |
State | Published - Apr 2011 |
Keywords
- Endometrial carcinoma
- Gemcitabine
- Gemzar
- Gynecologic Oncology Group
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology